Fennec Pharmaceuticals Inc. Q4 2024 Earnings Conference Call: Key Highlights
On March 10, 2025, Fennec Pharmaceuticals Inc. (NASDAQ: FENC) held its Fourth Quarter and Full Year 2024 Earnings and Corporate Update Conference Call. The call was led by Robert Andrade, CFO, and Jeff Hackman, CEO and Board Member. Here are the significant takeaways from the call:
Financial Performance
Fennec reported a net loss of $22.2 million for Q4 2024, which was an improvement compared to the net loss of $26.5 million in the same quarter last year. The full-year net loss was reported at $81.1 million, a decrease from $93.8 million in 2023. The decrease in losses is attributed to the successful completion of clinical trials and the progress in regulatory approvals for their lead product.
Product Development
Fennec’s lead product, RO4928327, is a novel, non-opioid pain medication for the treatment of moderate-to-severe acute pain. The company announced that they have completed the Phase 3 clinical trial for RO4928327 and plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second quarter of 2025. If approved, RO4928327 is expected to be the first non-opioid pain medication to be introduced in the market in over 60 years.
Collaborations and Partnerships
Fennec announced a collaboration with Merck KGaA, Darmstadt, Germany, to develop and commercialize RO4928327 outside of North America. Merck will provide development, regulatory, and commercialization expertise, while Fennec will retain ownership of the product and receive milestone payments and royalties. The deal is expected to strengthen Fennec’s financial position and accelerate the development and commercialization of RO4928327.
Impact on Individuals
For individuals dealing with pain, the successful development and approval of RO4928327 could mean a significant improvement in their quality of life. The non-opioid medication offers a potential solution for those seeking pain relief without the risks associated with opioids. Moreover, the collaboration with Merck could lead to wider availability and accessibility of the medication to people across the globe.
Impact on the World
The development of RO4928327 could have a substantial impact on public health, as the opioid crisis continues to be a significant concern worldwide. According to the World Health Organization (WHO), an estimated 50 million people suffer from chronic pain, and the misuse of opioids contributes to over 130 deaths every day. RO4928327’s non-opioid nature could help address this issue and provide a safer alternative for pain management.
Conclusion
Fennec Pharmaceuticals’ Q4 2024 Earnings Conference Call provided valuable insights into the company’s financial performance, product development, and collaborations. The successful completion of clinical trials for RO4928327 and the planned NDA submission to the FDA are significant milestones for Fennec and could lead to the introduction of a much-needed non-opioid pain medication. The collaboration with Merck is expected to accelerate the development and commercialization of RO4928327 and provide a safer alternative for pain management to individuals across the globe. The potential impact on public health is enormous, as the non-opioid medication could help address the ongoing opioid crisis. Stay tuned for further updates on Fennec Pharmaceuticals and the development of RO4928327.
- Fennec Pharmaceuticals reported improved financial performance in Q4 2024 and for the full year.
- The company’s lead product, RO4928327, has completed Phase 3 clinical trials and an NDA will be submitted to the FDA in Q2 2025.
- Fennec entered into a collaboration with Merck KGaA for the development and commercialization of RO4928327 outside of North America.
- The successful development and approval of RO4928327 could significantly improve the quality of life for individuals dealing with pain.
- The non-opioid medication could help address the ongoing opioid crisis and provide a safer alternative for pain management.
